Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of long-acting injectable cabotegravir for HIV PrEP persistence and coverage in MSM in France
2024-510678-25-00Phase 4Authorised
- Sponsor
- Inserm
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of cabotegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Inserm. Planned start Sep 2024; status: authorised.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-510678-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510678-25-00.